CIK 0001850119 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842040295
- Phone
- 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 63 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-12 | Blackwell Kimberly Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | JIMENEZ JOSEPH Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | Riva Alessandro Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | Carlo Rizzuto Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-12 | Walbert Timothy P Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-06-09 | Carr Douglas SVP Finance & Operations | Sale | −4,904 | $0.62 | $3K | 405,982 |
| 2025-06-09 | Farid Adrienne Chief Operations Officer | Sale | −552 | $0.62 | $343 | 250,141 |
| 2025-06-09 | Pfeiffenberger Brent President and CEO | Sale | −475 | $0.62 | $295 | 1,681,783 |
| 2025-06-09 | Russotti Gregory See Remarks | Sale | −526 | $0.62 | $327 | 392,047 |
| 2025-05-16 | Pfeiffenberger Brent President and CEO | Sale | −29,552 | $0.55 | $16K | 1,682,258 |
| 2025-05-05 | Farid Adrienne Chief Operations Officer | Sale | −1,024 | $0.55 | $563 | 250,693 |
| 2025-05-05 | Carr Douglas SVP Finance & Operations | Sale | −295 | $0.55 | $162 | 410,886 |
| 2025-03-11 | Conn Morgan Chief Finanical Officer | Grant or award | +19,500 | 79,648 | ||
| 2025-03-11 | Conn Morgan Chief Finanical Officer | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 | ||
| 2025-03-11 | Cowan Chad Chief Scientific Officer | Grant or award | +19,500 | 230,306 | ||
| 2025-03-11 | Cowan Chad Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 | ||
| 2025-03-11 | Pfeiffenberger Brent President and CEO | Grant or award | +521,500 | 1,711,810 | ||
| 2025-03-11 | Pfeiffenberger Brent President and CEO | Grant or award · Stock Option (right to buy) | +521,500 | 521,500 |
Page 4 of 6 · 118 trades